LAVA Therapeutics NV
NASDAQ:LVTX

Watchlist Manager
LAVA Therapeutics NV Logo
LAVA Therapeutics NV
NASDAQ:LVTX
Watchlist
Price: 0.9758 USD -4.33% Market Closed
Market Cap: 25.7m USD
Have any thoughts about
LAVA Therapeutics NV?
Write Note

Profitability Summary

We take all the information about a company's profitability (such as its margins, capital efficiency, free cash flow generating ability, and more) and consolidate it into one single number - the profitability score. The higher the profitability score, the more profitable the company is.

Past Growth

To be successful and remain in business, both growth and profitability are important and necessary. Net Income growth is often seen as a sign of a company's efficiency from an operational standpoint, but is influenced heavily by a company's goals and challenges and should therefore be assessed in conjunction with other metrics like revenue and operating income growth.

Margins

Profit margins represent what percentage of sales has turned into profits. Simply put, the percentage figure indicates how many cents of profit the company has generated for each dollar of sale.

Profit margins help investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.

Earnings Waterfall
LAVA Therapeutics NV

Revenue
7.3m USD
Cost of Revenue
-154k USD
Gross Profit
7.2m USD
Operating Expenses
-35.2m USD
Operating Income
-28m USD
Other Expenses
397k USD
Net Income
-27.6m USD

Margins Comparison
LAVA Therapeutics NV Competitors

Country Company Market Cap Gross
Margin
Operating
Margin
Net
Margin
NL
LAVA Therapeutics NV
NASDAQ:LVTX
25.7m USD
98%
-382%
-376%
FR
Pharnext SCA
OTC:PNEXF
6T USD
0%
-17 527%
-21 040%
US
Abbvie Inc
NYSE:ABBV
309.5B USD
67%
28%
9%
US
Amgen Inc
NASDAQ:AMGN
140.9B USD
60%
19%
13%
US
Gilead Sciences Inc
NASDAQ:GILD
112B USD
78%
38%
0%
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
105.6B USD
86%
40%
-5%
US
Epizyme Inc
F:EPE
94.1B EUR
76%
-370%
-392%
AU
CSL Ltd
ASX:CSL
137.8B AUD
52%
26%
18%
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
76.7B USD
87%
30%
34%
US
Seagen Inc
F:SGT
39.3B EUR
75%
-33%
-33%
NL
argenx SE
XBRU:ARGX
38.5B EUR
89%
-15%
-5%
No Stocks Found

Return on Capital

Return on capital ratios give a sense of how well a company is using its capital (equity, assets, capital employed, etc.) to generate profits (operating income, net income, etc.). In simple words, these ratios show how much income is generated for each dollar of capital invested.

Return on Capital Comparison
LAVA Therapeutics NV Competitors

Country Company Market Cap ROE ROA ROCE ROIC
NL
LAVA Therapeutics NV
NASDAQ:LVTX
25.7m USD
-63%
-28%
-35%
4 255%
FR
Pharnext SCA
OTC:PNEXF
6T USD
115%
-391%
275%
3 093%
US
Abbvie Inc
NYSE:ABBV
309.5B USD
56%
4%
15%
11%
US
Amgen Inc
NASDAQ:AMGN
140.9B USD
56%
5%
9%
10%
US
Gilead Sciences Inc
NASDAQ:GILD
112B USD
1%
0%
23%
13%
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
105.6B USD
-3%
-2%
24%
-80%
US
Epizyme Inc
F:EPE
94.1B EUR
-877%
-67%
-73%
-182%
AU
CSL Ltd
ASX:CSL
137.8B AUD
16%
7%
12%
9%
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
76.7B USD
17%
13%
13%
16%
US
Seagen Inc
F:SGT
39.3B EUR
-28%
-21%
-27%
-39%
NL
argenx SE
XBRU:ARGX
38.5B EUR
-3%
-3%
-9%
-22%
No Stocks Found

Free Cash Flow

Free cash flow (FCF) is the money a company has left over after paying its operating expenses and capital expenditures. The more free cash flow a company has, the more it can allocate to dividends, paying down debt, and growth opportunities.

If a company has a decreasing free cash flow, that is not necessarily bad if the company is investing in its growth.